Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 18, 2021
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 PathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
British Journal of Cancer|April 20, 2022
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancerBingnan Zhang, C Allison Stewart, Qi Wang, et al.
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
NPJ Precision Oncology|November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasmsAlejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 18, 2021
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 PathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
British Journal of Cancer|April 20, 2022
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancerBingnan Zhang, C Allison Stewart, Qi Wang, et al.
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
NPJ Precision Oncology|November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasmsAlejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Pageof 9